Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Deucravacitinib Trial in Alopecia Areata (Japan)
jRCT2031220610Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in alopecia areata (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: SALT score (primary efficacy) and Safety and tolerability (primary). Started Feb 2023; status: completed.
02
Drugs
deucravacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2031220610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220610.